Saturday 17 October 2026
Export TARA’s income statement to Excel — free account
Protara Therapeutics, Inc.
TARA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.86% and free cash flow fell 28.1%, each against the same quarter a year earlier.
2.33
0.07
−2.92%
Follow TARA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (45.80%) | (37.27%) | (31.60%) | (49.42%) |
+8 more TTM periods Free account |
|
| (42.05%) | (35.12%) | (29.39%) | (44.32%) | ||
ROIC |
(255.06%) | (96.39%) | (98.74%) | 0.00% | |
Return on Tangible Assets |
(52.19%) | (48.05%) | (38.47%) | (41.80%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.09) | (1.09) | (1.32) | (1.15) | |
Free Cash Flow |
(66.52) | (62.99) | (56.46) | (48.79) | |
Capital Expenditures |
(0.38) | — | (0.09) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(21.89%) | (19.87%) | (16.04%) | (18.42%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.94 | 1.00 | 0.98 | 0.92 | |
Depreciation/Fixed assets |
(0.55) | (1.32) | (1.16) | (0.97) | |
Capex/Depreciation |
0.52 | 0.00 | 0.11 | 0.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.08) | (1.09) | (1.32) | (1.15) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates